|Bid||47.56 x 100|
|Ask||60.50 x 100|
|Day's Range||50.03 - 52.50|
|52 Week Range||13.50 - 61.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.17|
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / U.S. markets' slide extended on Wednesday as concerns over a potential trade war with China continues to grow. The Dow Jones Industrial Average dropped 1.00 ...
This June, some 16,000 people will descend on the Boston Convention & Exhibition Center for the BIO International Convention, a closely-watched annual gathering that gives biotech companies another platform to pitch themselves to investors and each other. The Biotechnology Innovation Organization, the lobbying group that organizes the event, announced on Wednesday that the Motown star and former lead singer of The Supremes will perform a concert on the third night of the convention. Described on BIO’s website as a “networking event,” the concert will give attendees a chance to hear some of her biggest hits while they sip drinks, exchange business cards and discuss the latest in biotech news.
NEW YORK, March 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- NASDAQ up-listing may bring new institutional investors to the cell therapy manufacturer Orgenesis (ORGS), which has seen increased interest already as the company executes on their business model in ...
-On track to begin first company-sponsored clinical trials of a CRISPR-based therapy-- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly-. ZUG, Switzerland and CAMBRIDGE, Mass., March ...
eBay has turned every $1,000 invested in its IPO 20 years ago into $50,000 today. We think these three stocks have the same kind of potential.
Four Polish scientists just discovered a way to edit genes with CRISPR with high precision. Past CRISPR tech has hit public markets very quickly, and this new innovation may do so soon as well.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Ultragenyx and CRISPR Therapeutics both closed high in the green on Monday. Ultragenyx recently had positive news regarding Crysvita, an anti-FGF23 fully ...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 21, 2018-- CRISPR Therapeutics, a genome editing company focused on creating transformative medicine for serious diseases, today announced that members of its ...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2018-- CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that ...
Neither the CRISPR/Cas9 start-up nor its gene-editing peers had much to say last month, but it only took a suggestion of positive signs from elsewhere to send them rocketing higher.
Intellia Therapeutics, Crispr Therapeutics and Editas Medicine are at the forefront of the new CRISPR gene editing technology, which could cure thousands of diseases.
Crispr Therapeutics’ largest shareholder just invested another $12 million in the Swiss developer of gene-based medicines. Bayer disclosed that on Jan. 5 a subsidiary bought another 527,500 shares of Crispr (CRSP) for $22.75 each in a public offering. Bayer’s total ownership now stands at 5.71 million shares.